---
title: "Descartes-08 in Generalized myasthenia gravis: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Economic burden and healthcare resource utilization. Topics: Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023; Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims; Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023; Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021; 11 further topics. 15 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Incremental annual costs of newly diagnosed gMG compared with matched controls: U.S. claims, 2017 to 2023

> “Adults with newly diagnosed gMG were identified from Komodo Research data (January 1, 2017, to September 30, 2023).”
> “The gMG cohort (mean follow-up = 32.7 months) compared with the non-MG cohort (mean follow-up = 31.3 months) had 2.4, 1.6, and 1.9 times more inpatient days, emergency department visits, and outpatient visits annually, respectively (all P < 0.001).”
> “Mean annual all-cause total health care costs in the gMG cohort were $43,872 higher than in the non-MG cohort ($58,341 vs $14,469; P < 0.001); 59.3% of the difference was driven by pharmacy costs (mostly immunoglobulin).”
> “Prediagnosis weakness and fatigue symptoms, exacerbation or crisis, and use of immunoglobulin were important factors significantly associated with high health care costs in the gMG cohort (all P < 0.001).”

Source: [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/)

<a id="topic-2.2.1.8.2-2"></a>

### Costs associated with exacerbations and crises in newly diagnosed gMG: U.S. claims

> “After re-weighting, patients with a clinical event had higher number of inpatient admissions [rate ratio (RR) = 6.02], emergency visits (RR = 1.91), and outpatient visits (RR = 1.58; all p < 0.05) in the 12 months post-index. Mean total healthcare costs were $70,792 higher among patients with a clinical event ($95,821 vs. $25,029, p < 0.001), driven by immunoglobulin and inpatient costs.”

Source: [Grover et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/)

<a id="topic-2.2.1.8.2-3"></a>

### Incremental costs and event-related costs in prevalent and incident gMG: U.S. claims, 2017 to 2023

> “Analyses included 16,561 gMG patients (12,813 prevalent and 3748 incident) and 105,716 non-gMG controls. Among prevalent and incident gMG patients, respectively, MG exacerbation occurred during follow-up in 12.2 and 22.0% and myasthenic crisis in 6.0 and 12.4%.”
> “After weighting, gMG patients (median follow-up 696 days) experienced more frequent all-cause HCRU encounters and >4-fold higher healthcare costs ($5420 PPPM or ∼$65,000 per annum) versus non-gMG controls ($1298 PPPM or ∼$15,500 per annum).”
> “Among MG patients, those with MG exacerbation/myasthenic crisis, respectively, experienced means of 3.02/3.35 hospitalizations, 1.91/2.13 emergency department encounters, 12.70/13.39 skilled nursing facility encounters, and 67.86/75.52 outpatient encounters during follow-up; associated costs were $17,113/$18,640 PPPM (or ∼$205,000/$224,000 per annum).”

Source: [Jackson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41099443/)

<a id="topic-2.2.1.8.2-4"></a>

### Incremental monthly costs and the effect of comorbidities and acute events: U.S. claims, 2017 to 2021

> “The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001.”
> “Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively.”

Source: [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)

<a id="topic-2.2.1.8.2-5"></a>

### First-year costs after diagnosis by payer: U.S. commercial and Medicare claims, 2016 to 2021

> “The final analytic cohort included 3,700 patients with MG and 37,000 controls. On average, patients were aged 54 years, with 60% being female. The difference-in-difference estimates of the total health care cost for MG diagnosis in commercial and Medicare patients were $25,799 and $4,927, respectively (P < 0.01).”

Source: [Choi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12039500/)

<a id="topic-2.2.1.8.2-6"></a>

### Costs in newly diagnosed and previously diagnosed patients and around crisis events: U.S. claims, 2014 to 2019

> “Mean HCRU and costs were higher for newly diagnosed patients compared with previously diagnosed patients (hospitalizations: 0.46 vs. 0.34; all-cause costs: $26,419.20 vs. $24,941.47; direct costs for gMG treatments: $9,890.37 vs. $9,186.47) and further increased for patients with exacerbation events (hospitalizations: 0.72; all-cause costs: $43,734.15; direct costs for gMG treatments: $21,550.02).”
> “For patients who experienced crisis events, HCRU and costs markedly increased during the 12 months immediately before the crisis event (hospitalizations: 1.35; all-cause costs: $49,236.68) compared with the 2 preceding years and increased further during the 12 months following the crisis index date (hospitalizations: 2.78; all-cause costs: $173,956.99).”

Source: [Phillips et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8805609/)

<a id="topic-2.2.1.8.2-7"></a>

### Costs in patients treated with chronic IVIg or multiple nonsteroidal immunosuppressants

> “Compared with the reference cohort (n = 2992), the MG crisis rate was approximately twice as high in both the chronic IVIg (n = 324) and multiple NSIST (n = 291) cohorts (p < 0.001); and the MG exacerbation rate was approximately four-fold higher in the chronic IVIg cohort (p < 0.001) and three-fold higher in the multiple NSIST cohort (p < 0.001).”
> “Median annual MG-related inflation-adjusted total healthcare costs were higher in the chronic IVIg ($81,900) and multiple NSIST ($30,300) cohorts than in the reference cohort ($2540).”

Source: [Parthan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38018505/)

<a id="topic-2.2.1.8.2-8"></a>

### Costs by glucocorticoid exposure: U.S. commercial claims

> “Annual all-cause costs were >2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use.”

Source: [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/)

<a id="topic-2.2.1.8.2-9"></a>

### Hospitalization trends: U.S. Nationwide Inpatient Sample and Medicare, 2010 to 2019

> “Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all p < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.”
> “The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions.”

Source: [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/)

<a id="topic-2.2.1.8.2-10"></a>

### Range of direct and indirect costs across studies: systematic reviews

> “Across studies, the mean per-patient annual direct medical cost of illness was estimated at between $760 and $28,780, and cost per hospitalization between $2550 and $164,730. The indirect cost of illness was estimated at $80 and $3550.”
> “Costs varied considerably by patient characteristics, and drivers of the direct medical cost of illness included intravenous immunoglobulin and plasma exchange, myasthenic crisis, mechanical ventilatory support, and hospitalizations.”

Source: [Landfeldt et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32363541/)

> “1374 records were identified initially, and 44 were included in the final review.”
> “Direct costs include treatment and follow-up in the primary and specialist health care. They were estimated to €3 500–12 000 per MG patient per year in the Nordic countries, similar in other European countries, and higher in United States.”
> “Intangible costs include value of lost life-years and reduced quality of life, which are rarely assessed, but have been estimated to be half of the total societal MG costs.”

Source: [Gilhus et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13645850/)

<a id="topic-2.2.1.8.2-11"></a>

### Treatment escalation and first-year MG-related costs in newly diagnosed adults: U.S. MarketScan claims, 2010 to 2018

> “Patients aged ≥ 18 years at MG diagnosis were included from two US Merative™ MarketScan® databases.”
> “The cohort included 4925 adults with newly diagnosed MG (1102 aged 18–49 and 3823 aged ≥ 50 at first MG diagnosis) from January 1, 2010 to December 31, 2018.”
> “Overall, 71.5% (3521/4925) of patients had ≥ 1 MG treatment escalation; escalation with high-dose corticosteroids was the most common type (64.8% [18–49 group] and 58.5% [≥ 50 group]).”
> “Healthcare resource utilization (HCRU) and costs were highest in Year 1, with mean MG-related costs per patient between $24,982 (≥ 50 group) and $33,023 (18–49 group).”

Source: [Pujades-Rodríguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089002/)

<a id="topic-2.2.1.8.2-12"></a>

### Out-of-pocket and aggregate costs of eculizumab for myasthenia gravis: U.S. commercial and Medicare supplemental claims

> “We used the Merative MarketScan commercial and Medicare supplemental databases to observe patients seen by a neurologist with neurologic diseases with newly FDA-approved medications from 2014 to 2021”
> “We identified 2,687 unique individuals with ALS, 38 with ATTR, 69 with DMD, 884 with HD, 9,984 with MG, 441,099 with migraine, 4,723 with OH, 1,266 with TD, and 17 with SMA.”
> “Eculizumab for MG was an extreme outlier, with OOP costs increasing by 4,099% ($413-$17,359) and aggregate OOP costs by 7,005% ($5,375-$381,894).”

Source: [Gusovsky Chevalier et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11874732/)

<a id="topic-2.2.1.8.2-13"></a>

### Healthcare resource utilization before and after rozanolixizumab initiation: U.S. Komodo claims, July 2023 to March 2025

> “Patients were selected from de-identified claims data from the Komodo Healthcare Map® (July 2023–March 2025).”
> “The main study included 719 patients. Patients with ≥ 365 days since rozanolixizumab initiation (n = 287) started a mean (standard deviation) 2.9 (1.8) treatment cycles in Year 1. Total MG-related HCRU incidence rates per 100 person-years were 88.0 during baseline and 82.9 during follow-up, and 86.2 versus 80.8 for outpatient, 25.6 versus 17.3 for inpatient, and 24.9 versus 14.0 for emergency room visits.”

Source: [Kumar et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396046/)

<a id="topic-2.2.1.8.2-14"></a>

### Exacerbation rate and healthcare resource utilization by MG-ADL score: MGFA Global MG Patient Registry, United States, 2013 to 2022

> “Participants were based in the USA, aged ≥ 18 years, had a self-reported MG diagnosis and complete MG-ADL data, and were enrolled between July 1, 2013 and September 30, 2022.”
> “In total, 3416 patients (2092 [61.2%] females) were eligible; mean (standard deviation) age at diagnosis was 49.4 (17.4) years.”
> “For each additional point on the MG-ADL score, the rate of exacerbations increased by 13% (incidence rate ratio: 1.13; 95% confidence interval: 1.11–1.15; p < 0.001). At enrollment, 49.6% (n = 386/778) of patients who had one exacerbation had HCRU.”

Source: [Ting et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11906949/)

<a id="topic-2.2.1.8.2-15"></a>

### Acute care utilization by race and ethnicity in the 2 years after diagnosis: U.S. Optum claims, 2010 to 2019

> “A retrospective cohort study was conducted among adults (≥18 years) with newly diagnosed MG in the United States using Optum’s de-identified Market Clarity Data from January 1, 2010, to December 31, 2019.”
> “Compared with patients identifying as Caucasian, those identifying as African American had 37% higher odds of having an emergency department visit in year 1, and those identifying as Hispanic had 70% increase in odds of having a hospitalization event in year 2 post-diagnosis. Among other covariates, Medicaid usage, exacerbation at index, and number of outpatient visits were significantly associated with acute care utilization.”

Source: [Qi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11832025/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
